Holen Sie sich die Stockscreener-App
63.88
0.36%
0.355
Schlusskurs vom Vortag:
$63.53
Offen:
$63.72
24-Stunden-Volumen:
108.01K
Relative Volume:
0.56
Marktkapitalisierung:
$931.20M
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-140.06M
KGV:
-7.0637
EPS:
-9.0441
Netto-Cashflow:
$-129.83M
1W Leistung:
+6.48%
1M Leistung:
-7.83%
6M Leistung:
+82.38%
1J Leistung:
+377.96%
1-Tages-Spanne:
$62.26
$66.00
1-Wochen-Bereich:
$61.26
$71.65
52-Wochen-Spanne:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
63.75 | 927.98M | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
433.89 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.12 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.85 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.40 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.62 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
INBX Should I Buy - intellectia.ai
Discipline and Rules-Based Execution in INBX Response - news.stocktradersdaily.com
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5.7%What's Next? - MarketBeat
US Market Recap: Will Inhibrx Biosciences Inc stock recover after earnings2026 Risk Factors & Verified Momentum Watchlists - baoquankhu1.vn
Fundamentals Check: Will Inhibrx Biosciences Inc stock go up in YEAR2026 Opening Moves & Daily Volume Surge Signals - baoquankhu1.vn
Value Recap: Does Inhibrx Biosciences Inc have consistent dividend growthInsider Selling & Weekly Setup with ROI Potential - baoquankhu1.vn
Inhibrx Biosciences Inc. (INBX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Inhibrx Biosciences partners with Sarcoma Alliance to advance patient education resources - Traders Union
Retail Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Earnings Impact & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Volume Recap: Is Inhibrx Biosciences Inc affected by consumer sentimentTrend Reversal & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data (INBX) - Seeking Alpha
Ideas Watch: Is Inhibrx Biosciences Inc stock undervalued right nowEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.6%Here's Why - marketbeat.com
Inhibrx Biosciences (INBX) Expected to Announce Earnings on Tuesday - MarketBeat
Behavioral Patterns of INBX and Institutional Flows - news.stocktradersdaily.com
Inhibrx Biosciences Reports 2025 Financial Results - Intellectia AI
Inhibrx Reports Q4 Revenue of $0, Cash Balance at $124.2M - Intellectia AI
Inhibrx Biosciences Reports Q4 Earnings Miss - Intellectia AI
INBX SEC FilingsInhibrx Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibrx Inc stock surges on Q4 2025 earnings and key 2026 pipeline milestones - ad-hoc-news.de
Inhibrx Biosciences, Inc. 2025 Annual Report – Clinical Pipeline, Regulatory Progress, and Company Overview - Minichart
Inhibrx Biosciences (NASDAQ:INBX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Inhibrx Biosciences Q4 net loss narrows as expenses fall - TradingView
Inhibrx Biosciences 10-K: $1.3M revenue, EPS $(9.04) - TradingView
[10-K] Inhibrx Biosciences, Inc. Files Annual Report | INBX SEC FilingForm 10-K - Stock Titan
Inhibrx Biosciences (NASDAQ: INBX) details 2025 loss and 2026 trial plans - Stock Titan
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Nasdaq
Stock Analysis: Is Inhibrx Biosciences Inc a turnaround story2026 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
Boothbay Fund Management LLC Boosts Holdings in Inhibrx Biosciences, Inc. $INBX - marketbeat.com
Growth Value: What is Inhibrx Biosciences Incs P E ratio telling usQuarterly Trade Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Latest INBX NewsInhibrx Announces Participation in Upcoming... - Stock Titan
Slotnik Capital LLC Sells 142,770 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences Inc expected to post a loss of $2.08 a shareEarnings Preview - TradingView
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd - Defense World
(INBX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Inhibrx Biosciences : ESMO Sarcoma and Rare Cancers Congress 2026 (INBRX-109 in Ewing sarcoma Data Update Oral Presentation) - marketscreener.com
Market Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Inhibrx Biosciences (INBX) to Release Quarterly Earnings on Monday - MarketBeat
Will Inhibrx Biosciences Inc stock recover after earnings2025 Key Lessons & Technical Pattern Based Buy Signals - baoquankhu1.vn
Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
INBX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight - The Malaysian Reserve
INBX Technical Analysis & ETF Price Forecast - Intellectia AI
INBX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy - The Globe and Mail
Market Leaders: Is Inhibrx Biosciences Inc stock undervalued right nowWeekly Loss Report & Reliable Price Action Trade Plans - baoquankhu1.vn
Chipmakers Recap: Is RNAC vulnerable to short sellersBond Market & Fast Moving Stock Trade Plans - baoquankhu1.vn
Trading Systems Reacting to (INBX) Volatility - Stock Traders Daily
Readystate Asset Management LP Acquires 143,324 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Contrasting Immuneering (NASDAQ:IMRX) and Inhibrx Biosciences (NASDAQ:INBX) - Defense World
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):